Jun 20 |
Tharimmune announces $2.08M private placement
|
Jun 10 |
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
|
May 29 |
Tharimmune to Present at 2024 BIO International Convention
|
May 22 |
Tharimmune Announces 1-for-15 Reverse Stock Split
|
May 2 |
Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management
|
Apr 23 |
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
|
Apr 15 |
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
|
Mar 6 |
Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now
|
Mar 5 |
Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
|
Feb 20 |
Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
|